The role of DEK oncogene in normal and cancer stem cells

• Project/Area Number: 26430111
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Tumor biology
• Research Institution: Gifu University
• Principal Investigator: Hara Akira 岐阜大学, 大学院医学系研究科, 教授 (10242728)
• Co-Investigator(Kenkyū-buntansha): 富田 弘之 岐阜大学, 大学院医学系研究科, 准教授 (50509510)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000); Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: 腫瘍 / 再生 / 癌遺伝子 / クロマチン / 癌

Outline of Final Research Achievements

We have generated doxycyclin-inducible Dek transgenic mouse. Dek induction unchanged the histology of the mouse tissues in the normal condition. However, when exposed to the carcinogen, the DEk-inducible mouse enhanced the tumor proliferation and tumor progression in the organ with squamous cell epithelium. Dek overexpression enhanced the G1/S transition in tumor cells. We have clarified Dek is the true oncogene. The target therapy against the DEK in cancers will be promised in the future.